Zydus’ COVID-19 vaccine shows 66.6% efficacy in Phase-3 interim analysis, company files for emergency use

No moderate case of COVID-19 disease was observed in the vaccine arm post administration of the third dose suggesting 100% efficacy for moderate disease. No severe cases or deaths due to COVID-19 occurred in the vaccine arm after administration of the second dose of the vaccine.